Myasthenia Associated with D-penicillamine Therapy in Rheumatoid Arthritis' by Dr R C Bucknall (Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HWand Royal National Hospitalfor Rheumatic Diseases, Bath) Muscle weakness with features characteristic of myasthenia occurring in patients with rheumatoid arthritis (RA) treated with D-penicillamine was first described at an international symposium held in London in October 1974: V R Ott reported 2 cases and Broll, Miehlke, and Camus each reported one case. Subsequently, Bucknall et al. (1975) documented 4 cases, Balint et al. (1975) 2 cases, and Delrieu et al. (1975) one case. Since that time, I have collected data on a further 9 patients with RA who have developed this complication of D-penicillamine therapy, providing a total of 21 cases in the world literature. This appears to be a rare finding, with no more than one patient presenting to a large rheumatology department. The object of this communication is, therefore, to outline the various features demonstrated between RA, D-penicillamine, and myasthenia.
All patients (18 female, 3 male) had longstanding RA with the duration of disease ranging from 1 to 40 years. The mean age was 45 years, an older age group than that found in myasthenia gravis, where the model age of onset is 20 years (Simpson 1974) . Five patients had evidence of Sjogren's syndrome, in which condition drug side-effects are common (Bloch et al. 1965) . The dose of penicillamine exceeded 1 g daily in 10 patients, and only one patient was receiving less than 500 mg per day. The duration of therapy before the onset of muscle weakness ranged from four months to five years. Muscle weakness on fatigue usually initially involved the upper lid, sometimes associated with the extraocular muscles, leading to ptosis and diplopia, respectively.
Involvement of the bulbar muscles resulting in dysphagia and dysarthria was a common finding. In the more severe cases, there was weakness of proximal limb muscles, characterized by impaired arm abduction and difficulty in climbing stairs. A few patients had difficulty in sitting up, and in 2 patients there was involvement of respiratory muscles, as shown by a reduced vital capacity. In general, the more severely affected patients were those in whom doses of D-penicillamine exceeded 1 g daily or who had received 'This paper was not read at the Symposium Fig 1 A 49-year-oldpatient with RA eight months after startingpenicillamine. Note bilateralptosis treatment for at least six months. In at least 2 patients myasthenia was not recognized until a month or more after onset of muscle weakness.
The diagnosis of myasthenia was based on clinical findings, and the response to intravenous edrophonium chloride (Tensilon) or intramuscular neostigmine. Of all 16 patients tested with these anticholinesterase drugs, there was a marked improvement in muscle weakness. Detailed electrophysiological testing has only been carried out in a few of these patients. Neuromuscular block, as shown by a decrement on tetanic stimulation, was demonstrated in 4 patients. One patient presenting with diplopia and proximal muscle weakness showed no such decrement, and 3 other patients studied after myasthenic features had resolved showed no abnormality. Two patients were studied using a concentric needle electrode. One patient showed jitter exceeding 100 psec, but with no blocking. The other patient showed marked impairment of motor unit activity with a small burst of poly-phasic activity, but following intravenous Tensilon there was increase in volitional activity associated with increased amplitude of individual polyphasic complexes.
Only one patient was subjected to the decamethonium test, and this showed a resistance to this drug and only a slight decrement on tetanic stimulation. This response to decamethonium is said to be specific for myasthenia gravis. Other conditions such as polymyositis and motorneurone disease may exhibit features of myasthenia, but there was no evidence clinically of these diseases, and muscle enzymes were normal in all of 6 patients tested.
The temporal relationship between penicillamine therapy and myasthenia is important. Spontaneous resolution of muscle weakness following withdrawal of penicillamine therapy occurred in 7 patients. In a further 6 patients treatment with anticholinesterase drugs was carried out. These were subsequently withdrawn Hence, a total of 13 patients have made a full recovery. A further 4 patients are still receiving anticholinesterase drugs at the time of writing, but in all cases on a reduced dose. In 4 patients anticholinesterase therapy failed to control the myasthenia, and 2 of these were subjected to thymectomy with a good response in one and fair response in the other. Both patients remain on anticholinesterase therapy. A third patient was subjected to thymic irradiation, with improvement in muscle weakness, but he also remains on anticholinesterase therapy. Finally, one patient with severe myasthenia requiring artificial ventilation died. The cause of death was not clear, there being a concomitant hypothyroidism. In this patient, penicillamine was continued in spite of the development of muscle weakness. (1.3 g protein in 24 h). This resolved spontaneously as did her myasthenia, and although a renal biopsy was not performed it seems likely that this was due to an immune complex nephropathy (Bacon et al. 1976) . One patient developed a lupus syndrome concomitantly with myasthenia (Camus, personal communication, 1975) . Before penicillamine treatment, rheumatoid factor was present in the serum at a titre of 1/128 (Rose-Waaler), and she was antinuclear antibody (ANA) negative. One year after the onset of penicillamine therapy the patient developed myasthenia and a rash. At this time the Rose-Waaler test was negative, but the ANA was present at a titre of 1/1000. A lupus syndrome associated with penicillamine therapy has previously been described by Crouzet et al. (1974) , and Zilko in this symposium (p 118) describes rising titres of ANA in patients receiving this drug. Finally, one patient is described (Delrieu et al. 1975) in whom penicillamine-induced myasthenia was associated with thyroiditis with haemagglutinating thyroid antibodies at a titre of 1/3125 and low serum thyroxine.
It appears that patients with rheumatoid disease exhibit a predisposition to develop these side-effects when receiving D-penicillamine. Only 2 cases of myasthenia have been reported in patients with Wilson's disease on this drug (Czlonkowska 1975 , Dawkins et al. 1975 . This is in spite of the fact that patients with this disease have been treated for a longer time and at a higher dose (Waishe p 1). There are not recorded cases of myasthenia occurring in patients with cystinuria (Watts, personal communication, 1975) although it must be emphasized that this represents a smaller group of patients but again receiving larger doses of D-penicillamine than those used in RA. There is some evidence that other more commonly encountered side-effects such as thrombocytopenia and proteinuria may occur more commonly in RA than in Wilson's disease (Lyle, personal communication). This suggests that the use of Dpenicillamine in the context of a disorder characterized by disturbed immunological function may be relevant.
It is possible that penicillamine is bringing to light a latent myasthenia present in some, if not all, of these patients. It is possible that there is an increased incidence of myasthenia gravis (MG) in patients with RA; no data are available from the literature. Oosterhuis & de Hass (1969) , in a survey of 96 women and 46 men with MG, found only 7 cases of RA. This gives an incidence of 4.9 %, compared with a control population of 4 %. An increased incidence of the histocompatibility antigens HLA1 and 8 have been reported in patients with MG (Feltkamp et al. 1974 , Behan et al. 1973 ). In 7 patients with penicillamineinduced myasthenia, only 3 possessed HLA1 and HLA8. The presence of HLA8 is usually associated with MG without thymomas and with an early onset of disease, less than 40 years of age in 56 out of 74 patients studied (Feltkamp et al. 1974 ).
The mechanism of penicillamine-induced myasthenia is not known. A simple pharmacological block at the neuromuscular junction seems unlikely and, using a rat phrenic/diaphragm preparation, Collins (personal communication) has been unable to demonstrate this mode of action of penicillamine. It seems more likely that the condition is immunologically mediated. Lindstrom (1975) has shown by immunizing rats with eel acetylcholine receptor protein that there is an early phase of cell-mediated hypersensitivity to the acetylcholine receptor associated with degeneration of the motor end plate, and this is followed by a chronic phase with the appearance of acetylcholine receptor antibodies in the serum and associated with neuromuscular blockade reversed by anticholinesterase therapy. Lindstrom et al. (1976) have demonstrated antibodies to acetylcholine receptor protein (Ab.AcCh.R.) in 98% of 84 MG sera tested. Sera from patients with penicillamine-induced myasthenia are currently being studied for Ab.AcCh.R.
In summary, penicillamine therapy in patients with RA may be associated rarely with a condition which is clinically indistinguishable from myasthenia gravis. Withdrawal of drug therapy in the early phase of muscle weakness usually results in spontaneous resolution of symptoms, although anticholinesterase therapy may be required for a period of time. Some patients may develop a progressive generalized muscle weakness necessitating thymectomy. The temporal relationship between the appearance of these features and onset of penicillamine therapy indicates that this drug is responsible for induction of this condition.
It is possible, however, that penicillamine is merely precipitating a latent myasthenia gravis in these patients. The fact that this complication of penicillamine therapy occurs less commonly} in patients with Wilson's disease and cystinuria suggests that RA per se may predispose to the development of myasthenia. The nature of the neuromuscular block in this condition has not been clearly defined, and detailed electrophysiological and immunological studies are required. In conclusion, it is important to recognize myasthenia as a complication of penicillamine therapy, as withdrawal of the drug usually results in complete resolution of clinical features, and patients will only be subjected to thymectomy in severe progressive cases.
